Fractyl Health publishes presentation on pancreas-targeted GLP-1 gene therapy in preclinical type 2 diabetes models

Fractyl Health, Inc.

Fractyl Health, Inc.

GUTS

0.00
  • Fractyl Health released a preclinical research presentation on pancreas-targeted AAV GLP-1 gene therapy for type 2 diabetes.
  • Work highlights improved beta-cell function with lower cellular stress in animal models, positioning the program as a potential one-time intervention.
  • Asset RJVA-001 remains investigational, has clinical trial authorization in the Netherlands, is under review in additional EU countries and Australia.
  • RJVA-001 and the Rejuva delivery device have not been assessed by the FDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.